Art. -Nr.: HY-152177

JS6

Name: JS6
Brand: MedChemExpress
SKU: HY-152177
Price: 70.00 USD
Availability: InStock
Rating: 5 (1 reviews)

1 Cited Publications

Kundenbewertung

Based on 1 publication(s) in Google Scholar

JS6 is a Bcl3 inhibitor. JS6 attenuates the binding of Bcl3 to NF-κB1 (p50), disrupts the binding of Bcl3 to NF-κB family proteins p50 and p52, and inhibits the NF-κB signaling pathway. JS6 is applicable to breast cancer-related research.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit : 99.49%
CAS. Nr.: 950244-33-4
Formel: C₂₀H₂₂FN₃O₃
Molecular Weight:371.41

Speicherung:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month

JS6 Chemical Structure

CAS. Nr.: 950244-33-4

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- IC₅₀ & Target
- Cellular Effect
- In Vitro
Chemical Information
Publications (1)
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Protokoll (2)
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

IC₅₀ & Target

^[1]^[2]

Bcl3

p50

p52

Alle NF-κB Isoform-spezifische Produkte anzeigen :

Cellular Effect

Cell Line	Type	Value	Description	References
MCF-10A	IC50	7.4 μM	Reduction of cell viability in non-tumorigenic breast MCF-10A cells measured after 24 hours by Cell Titre Blue assay. Reduction of cell viability in non-tumorigenic breast MCF-10A cells measured after 24 hours by Cell Titre Blue assay.	WO2015014972A1
MDA-MB-231	IC50	5.2 μM	Reduction of cell viability in triple-negative breast cancer MDA-MB-231 cells measured after 24 hours by Cell Titre Blue assay. Reduction of cell viability in triple-negative breast cancer MDA-MB-231 cells measured after 24 hours by Cell Titre Blue assay.	WO2015014972A1
SK-BR-3	IC50	4.7 μM	Reduction of cell viability in HER2-positive breast cancer SKBR3 cells measured after 24 hours by Cell Titre Blue assay. Reduction of cell viability in HER2-positive breast cancer SKBR3 cells measured after 24 hours by Cell Titre Blue assay.	WO2015014972A1
HEK293	IC50	4.2 μM	Inhibition of Bcl-3 binding to NFKB1 (p50) in HEK-293 cells overexpressing FLAG-tagged Bcl-3 measured after 24 hours by indirect sandwich ELISA assay. Inhibition of Bcl-3 binding to NFKB1 (p50) in HEK-293 cells overexpressing FLAG-tagged Bcl-3 measured after 24 hours by indirect sandwich ELISA assay.	WO2015014972A1
MDA-MB-231	IC50	2.7 μM	Inhibition of NF-κB signalling in MDA-MB-231 cells overexpressing Bcl-3 measured after 24 hours pre-incubation followed by 48 hours post-transfection incubation using NF-κB promoter-reporter (luciferase) assay. Inhibition of NF-κB signalling in MDA-MB-231 cells overexpressing Bcl-3 measured after 24 hours pre-incubation followed by 48 hours post-transfection incubation using NF-κB promoter-reporter (luciferase) assay.	WO2015014972A1
HEK293	IC50	5.9 μM	Inhibition of NF-κB signalling in HEK-293 cells overexpressing Bcl-3 measured after 24 hours pre-incubation followed by 48 hours post-transfection incubation using NF-κB promoter-reporter (luciferase) assay. Inhibition of NF-κB signalling in HEK-293 cells overexpressing Bcl-3 measured after 24 hours pre-incubation followed by 48 hours post-transfection incubation using NF-κB promoter-reporter (luciferase) assay.	WO2015014972A1
HEK293	IC50	5.7 μM	Inhibition of NF-κB signalling in HEK-293 cells overexpressing Bcl-3 and p52 measured after 24 hours pre-incubation followed by 48 hours post-transfection incubation using NF-κB promoter-reporter (luciferase) assay. Inhibition of NF-κB signalling in HEK-293 cells overexpressing Bcl-3 and p52 measured after 24 hours pre-incubation followed by 48 hours post-transfection incubation using NF-κB promoter-reporter (luciferase) assay.	WO2015014972A1
MDA-MB-231	IC50	4.8 μM	Reduction of cell motility in MDA-MB-231 cells overexpressing Bcl-3 measured after 24 hours pre-incubation followed by 24 hours Boyden Chamber incubation. Reduction of cell motility in MDA-MB-231 cells overexpressing Bcl-3 measured after 24 hours pre-incubation followed by 24 hours Boyden Chamber incubation.	WO2015014972A1

In Vitro

JS6 potently inhibits Bcl3 activity in cancer cells, reducing Bcl3-NF-κB1 binding, tumor colony formation, and cancer cell migration^[1].
JS6 (Compound 1a) (24 h) reduces the viability of MCF-10A, MDA-MB-231 and SKBR3 breast cancer cells^[2].
JS6 (24 h pre-incubation followed by 24 h chamber incubation) reduces the motility of MDA-MB-231 cells overexpressing Bcl-3^[2].
JS6 (24 h) inhibits the binding of Bcl-3 to p50 in HEK-293 cells overexpressing FLAG-tagged Bcl-3^[2].
JS6 (pre-incubated for 24 h, followed by 48 h of incubation after transfection) inhibits the NF-κB signaling pathway in Bcl-3-overexpressing MDA-MB-231 cells, Bcl-3-overexpressing HEK-293 cells, and HEK-293 cells overexpressing both Bcl-3 and p52^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.

Chemical Information

CAS. Nr. 950244-33-4
Appearance Solid
Molecular Weight 371.41
Formel C₂₀H₂₂FN₃O₃
Color White to off-white
SMILES

O=C(NCCN1CCOCC1)C2=CC=CC=C2NC(C3=CC=CC=C3F)=O
Versand

Room temperature in continental US; may vary elsewhere.

Speicherung

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Publications (1)

All

Sort by:

Journal Impact Factor

bioRxiv

2026 Mar 10.

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : 50 mg/mL (134.62 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.6924 mL

13.4622 mL

26.9244 mL

5 mM

0.5385 mL

2.6924 mL

5.3849 mL

10 mM

0.2692 mL

1.3462 mL

2.6924 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (6.73 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.5 mg/mL (6.73 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (6.73 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Protokoll

All Signal Pathway Related Animals and Diseases

Research Protocol for Inflammation-related Diseases
The NLRP3 inflammasome is a cytosolic innate immune signaling platform that integrates priming signals and danger-signal activation to promote caspase-1 activation, maturation of IL-1β and IL-18, and gasdermin D-mediated pyroptotic cell death. The core experimental logic is to determine whether inflammatory disease phenotypes are driven by increased NLRP3 expression, ASC-containing inflammasome assembly, caspase-1 cleavage, GSDMD cleavage, and extracellular release of IL-1β/IL-18 rather than by nonspecific cell injury alone. The pathway is strongly linked to inflammation-related disease phenotypes because monosodium urate crystals activate NALP3/NLRP3 inflammasome signaling in gout-like crystal inflammation, cholesterol crystals activate NLRP3 inflammasomes in atherogenesis models, and DSS-induced intestinal inflammation has been reported to involve NLRP3 inflammasome activity. However, experimental colitis studies also show context-dependent protective effects of NLRP3 inflammasome co
Breast Cancer Modeling
Breast cancer is a heterogeneous cancer, and it has been distinguished into four subtypes: luminal A, luminal B, HER2-positive and basal-like. Molecular mutations, epigenetic alterations, hormone exposure and immune microenvironment are related to the progression of breast cancer.

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (283 KB)
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Soukupová J, et al. The Discovery of a Novel Antimetastatic Bcl3 Inhibitor. Mol Cancer Ther. 2021 May;20(5):775-786. [Content Brief]

[2]. Westwell, A. D. (2015). 2‑Benzoylaminobenzamide derivatives as BCL‑3 inhibitors (PCT Patent No. WO2015014972A1). WIPO.

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.6924 mL	13.4622 mL	26.9244 mL	67.3111 mL
	5 mM	0.5385 mL	2.6924 mL	5.3849 mL	13.4622 mL
	10 mM	0.2692 mL	1.3462 mL	2.6924 mL	6.7311 mL
	15 mM	0.1795 mL	0.8975 mL	1.7950 mL	4.4874 mL
	20 mM	0.1346 mL	0.6731 mL	1.3462 mL	3.3656 mL
	25 mM	0.1077 mL	0.5385 mL	1.0770 mL	2.6924 mL
	30 mM	0.0897 mL	0.4487 mL	0.8975 mL	2.2437 mL
	40 mM	0.0673 mL	0.3366 mL	0.6731 mL	1.6828 mL
	50 mM	0.0538 mL	0.2692 mL	0.5385 mL	1.3462 mL
	60 mM	0.0449 mL	0.2244 mL	0.4487 mL	1.1219 mL
	80 mM	0.0337 mL	0.1683 mL	0.3366 mL	0.8414 mL
	100 mM	0.0269 mL	0.1346 mL	0.2692 mL	0.6731 mL

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

JS6

Publications Citing Use of MedChemExpress (MCE) JS6

Alle NF-κB Isoform-spezifische Produkte anzeigen